Impact of Methylated Cyclodextrin KLEPTOSE^® CRYSMEB on Inflammatory Responses in Human In Vitro Models

Area of Science:

• Pharmacology and Immunology
• Biochemistry
• Cell Biology

Background:

• KLEPTOSE CRYSMEB, a methylated cyclodextrin, has shown potential in treating atherosclerosis and neurological diseases.
• Its specific impact on inflammatory pathways and immune modulation remains unclear.
• Understanding its mechanism is crucial for therapeutic applications.

Purpose of the Study:

• To assess the impact of KLEPTOSE CRYSMEB on pharmacological targets in endothelial cells.
• To screen its effects across diverse human cell-based systems using the BioMAP Diversity PLUS panel.
• To investigate its anti-inflammatory and pro-resolving properties in peripheral blood mononuclear cells.

Main Methods:

• Utilized human umbilical vein endothelial cells under physiological and inflammatory conditions.
• Employed the BioMAP Diversity PLUS panel for screening across twelve human primary cell-based systems.
• Investigated anti-inflammatory mechanisms in peripheral blood mononuclear cells.

Main Results:

• KLEPTOSE CRYSMEB demonstrated in vitro immune system modulation and potential vascular benefits.
• Observed anti-inflammatory effects through inhibition of pro-inflammatory cytokine secretion.
• No significant impact on pro-resolving lipid mediators was detected.

Conclusions:

• KLEPTOSE CRYSMEB exhibits anti-inflammatory properties, potentially via TLR interaction or LPS/PGE2 complexation.
• Its mechanism may involve modulating immune cell communication and membrane cholesterol.
• The cyclodextrin's effects vary by tissue type and differ from known anti-inflammatory agents.